Valine

Valine

SCHEMBL3286146

CC(C)[C@@H](N)C(=O)O.NC=O

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.79
SLC1A3 P43003 4/20 0.46
SLC1A2 P43004 4/20 0.46
SLC1A1 P43005 4/20 0.46
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
GABRB2 P47870 2/20 0.37
GABRA4 P48169 2/20 0.37
GABRE P78334 2/20 0.37
GABRA6 Q16445 2/20 0.37
GABRG1 Q8N1C3 2/20 0.37
GABRG3 Q99928 2/20 0.37
GABRQ Q9UN88 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL1729111 1.00 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL29008223 1.00 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL2875734 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL30548418 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL10725920 0.90 SLC7A5 (0.79) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL8516 0.89
Valine SCHEMBL1813972 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL2785563 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP
Valine SCHEMBL43678 0.89
Valine SCHEMBL41225 0.89 SLC7A5 (1.00) SLC7A5SLC1A3SLC1A2SLC1A1GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709235-B2 5-Substituted hydantoin racemase, DNA encoding the same, recombinant DNA, transformed cell, and process for production of optically active N-carbamylamino acid or optically active amino acid KANEKA CORPORATION (JP) 2010-05-04 US claimed
US-20080261268-A1 5-Substituted Hydantoin Racemase, Dna Encoding the Same, Recombinant Dna, Transformed Cell, and Process for Production of Optically Active N-Carbamylamino Acid or Optically Active Amino Acid KANEKA CORPORATION (JP) 2008-10-23 US claimed
EP-1852510-A1 5-SUBSTITUTED HYDANTOIN RACEMASE, DNA ENCODING THE SAME, RECOMBINANT DNA, TRANSFORMED CELL, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE N-CARBAMYLAMINO ACID OR OPTICALLY ACTIVE AMINO ACID Kaneka Corporation (JP) 2007-11-07 EP claimed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
US-11573224-B2 Methods of detection using X-ray fluorescence ICAGEN, LLC (US) 2023-02-07 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-10877035-B2 Advanced drug development and manufacturing ICAGEN, LLC (US) 2020-12-29 US disclosed
US-20200278346-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ADJACENT ACQUISITION CO., LLC 2020-09-03 US disclosed
EP-3681504-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE Icagen, Inc. (US) 2020-07-22 EP disclosed
WO-2019055754-A1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN, INC. (US) 2019-03-21 WO disclosed
WO-2018204764-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION (US) 2018-11-08 WO disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
US-7709235-B2 5-Substituted hydantoin racemase, DNA encoding the same, recombinant DNA, transformed cell, and process for production of optically active N-carbamylamino acid or optically active amino acid KANEKA CORPORATION (JP) 2010-05-04 US disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080261268-A1 5-Substituted Hydantoin Racemase, Dna Encoding the Same, Recombinant Dna, Transformed Cell, and Process for Production of Optically Active N-Carbamylamino Acid or Optically Active Amino Acid KANEKA CORPORATION (JP) 2008-10-23 US disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed
EP-1852510-A1 5-SUBSTITUTED HYDANTOIN RACEMASE, DNA ENCODING THE SAME, RECOMBINANT DNA, TRANSFORMED CELL, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE N-CARBAMYLAMINO ACID OR OPTICALLY ACTIVE AMINO ACID Kaneka Corporation (JP) 2007-11-07 EP disclosed
US-4925978-A Method of preparation of optically active alpha-amino-acids ENIRICERCHE S.P.A. (IT) 1990-05-15 US disclosed